These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22359398)

  • 21. Validity of large-deformation high dimensional brain mapping of the basal ganglia in adults with Tourette syndrome.
    Wang L; Lee DY; Bailey E; Hartlein JM; Gado MH; Miller MI; Black KJ
    Psychiatry Res; 2007 Feb; 154(2):181-90. PubMed ID: 17289354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.
    Domínguez D JF; Egan GF; Gray MA; Poudel GR; Churchyard A; Chua P; Stout JC; Georgiou-Karistianis N
    PLoS One; 2013; 8(9):e74131. PubMed ID: 24066104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Pyatigorskaya N; Yahia-Cherif L; Gaurav R; Ewenczyk C; Gallea C; Valabregue R; Gargouri F; Magnin B; Degos B; Roze E; Bardinet E; Poupon C; Arnulf I; Vidailhet M; Lehericy S
    Mov Disord; 2020 Jan; 35(1):161-170. PubMed ID: 31710146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffusion tensor imaging of basal ganglia and thalamus in amyotrophic lateral sclerosis.
    Sharma KR; Sheriff S; Maudsley A; Govind V
    J Neuroimaging; 2013 Jul; 23(3):368-74. PubMed ID: 22273090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of subcortical grey matter abnormalities in patients with MRI-negative cortical epilepsy determined through structural and tensor magnetic resonance imaging.
    Peng SJ; Harnod T; Tsai JZ; Ker MD; Chiou JC; Chiueh H; Wu CY; Hsin YL
    BMC Neurol; 2014 May; 14():104. PubMed ID: 24885823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease.
    Vandenberghe W; Demaerel P; Dom R; Maes F
    J Neurol; 2009 Jan; 256(1):109-14. PubMed ID: 19267169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease.
    Gorges M; Müller HP; Mayer IM; Grupe GS; Kammer T; Grön G; Kassubek J; Landwehrmeyer GB; Wolf RC; Orth M
    Sci Rep; 2017 Mar; 7():43841. PubMed ID: 28266655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study.
    Douaud G; Gaura V; Ribeiro MJ; Lethimonnier F; Maroy R; Verny C; Krystkowiak P; Damier P; Bachoud-Levi AC; Hantraye P; Remy P
    Neuroimage; 2006 Oct; 32(4):1562-75. PubMed ID: 16875847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging.
    Bartzokis G; Sultzer D; Cummings J; Holt LE; Hance DB; Henderson VW; Mintz J
    Arch Gen Psychiatry; 2000 Jan; 57(1):47-53. PubMed ID: 10632232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shape changes of the basal ganglia and thalamus in Alzheimer's disease: a three-year longitudinal study.
    Cho H; Kim JH; Kim C; Ye BS; Kim HJ; Yoon CW; Noh Y; Kim GH; Kim YJ; Kim JH; Kim CH; Kang SJ; Chin J; Kim ST; Lee KH; Na DL; Seong JK; Seo SW
    J Alzheimers Dis; 2014; 40(2):285-95. PubMed ID: 24413620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal change in basal ganglia volume in patients with Huntington's disease.
    Aylward EH; Li Q; Stine OC; Ranen N; Sherr M; Barta PE; Bylsma FW; Pearlson GD; Ross CA
    Neurology; 1997 Feb; 48(2):394-9. PubMed ID: 9040728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Automated structural imaging analysis detects premanifest Huntington's disease neurodegeneration within 1 year.
    Majid DS; Stoffers D; Sheldon S; Hamza S; Thompson WK; Goldstein J; Corey-Bloom J; Aron AR
    Mov Disord; 2011 Jul; 26(8):1481-8. PubMed ID: 21484871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.
    van Bergen JM; Hua J; Unschuld PG; Lim IA; Jones CK; Margolis RL; Ross CA; van Zijl PC; Li X
    AJNR Am J Neuroradiol; 2016 May; 37(5):789-96. PubMed ID: 26680466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis.
    Younes L; Ratnanather JT; Brown T; Aylward E; Nopoulos P; Johnson H; Magnotta VA; Paulsen JS; Margolis RL; Albin RL; Miller MI; Ross CA;
    Hum Brain Mapp; 2014 Mar; 35(3):792-809. PubMed ID: 23281100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.
    Shaffer JJ; Ghayoor A; Long JD; Kim RE; Lourens S; O'Donnell LJ; Westin CF; Rathi Y; Magnotta V; Paulsen JS; Johnson HJ
    Hum Brain Mapp; 2017 Mar; 38(3):1460-1477. PubMed ID: 28045213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.
    Rosas HD; Tuch DS; Hevelone ND; Zaleta AK; Vangel M; Hersch SM; Salat DH
    Mov Disord; 2006 Sep; 21(9):1317-25. PubMed ID: 16755582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications.
    Bartzokis G; Lu PH; Tishler TA; Fong SM; Oluwadara B; Finn JP; Huang D; Bordelon Y; Mintz J; Perlman S
    Neurochem Res; 2007 Oct; 32(10):1655-64. PubMed ID: 17484051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.